Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793833

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793833

Soft Tissue Sarcoma

PUBLISHED:
PAGES: 282 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Soft Tissue Sarcoma Market to Reach US$2.4 Billion by 2030

The global market for Soft Tissue Sarcoma estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Targeted Therapy Treatment, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$904.7 Million by the end of the analysis period. Growth in the Chemotherapy Treatment segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$417.6 Million While China is Forecast to Grow at 11.8% CAGR

The Soft Tissue Sarcoma market in the U.S. is estimated at US$417.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$502.8 Million by the year 2030 trailing a CAGR of 11.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Soft Tissue Sarcoma Market - Key Trends & Drivers Summarized

Targeting Complexity: Innovations in Diagnosis and Therapy Transforming Soft Tissue Sarcoma Management

What Makes Soft Tissue Sarcoma a Unique Therapeutic Challenge in Oncology?

Soft tissue sarcoma (STS) comprises a heterogeneous group of rare malignant tumors originating from connective tissues such as fat, muscle, blood vessels, nerves, and tendons. Representing less than 1% of all adult cancers, STS spans over 50 histologic subtypes, including liposarcoma, leiomyosarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma. This histological diversity presents a significant challenge for oncologists, pathologists, and drug developers. Standardized treatment is often limited by the difficulty of early diagnosis, variable tumor behavior, and differing responses to therapeutic interventions. Most cases are diagnosed only after tumors reach advanced stages or metastasize, primarily due to their asymptomatic progression and misclassification with benign lesions.

Histopathological and molecular profiling have thus become indispensable in STS diagnosis. Immunohistochemistry, FISH (fluorescence in situ hybridization), and next-generation sequencing (NGS) are being increasingly employed to accurately characterize tumor subtypes and identify actionable genetic alterations. Advances in molecular diagnostics are now enabling personalized approaches to STS treatment. However, the rarity and complexity of these tumors continue to limit the availability of large-scale clinical trials, resulting in fewer approved targeted therapies compared to other cancers. The inherent genetic instability and adaptability of STS cells further complicate therapeutic strategies, often resulting in poor prognoses for patients with advanced disease.

Which Treatment Strategies and Therapeutic Developments Are Reshaping the STS Landscape?

Surgical resection remains the primary treatment modality for localized soft tissue sarcomas, often supplemented by radiotherapy and chemotherapy depending on tumor grade, location, and resection margins. In high-grade and deep-seated sarcomas, radiation therapy-either external beam or brachytherapy-is administered to reduce recurrence risk. However, systemic therapies for advanced and metastatic STS have traditionally been limited in efficacy. Doxorubicin-based chemotherapy, either alone or in combination with ifosfamide, has long been the frontline standard, but is often associated with significant toxicity and modest survival benefits.

Targeted therapy and immunotherapy are now driving the paradigm shift in STS treatment. Agents such as pazopanib, a multi-tyrosine kinase inhibitor, and trabectedin, a DNA-binding anti-neoplastic, are showing subtype-specific efficacy. For instance, pazopanib has demonstrated effectiveness in non-adipocytic STS, while eribulin has shown promise in liposarcoma patients. Moreover, immunotherapies such as PD-1 and CTLA-4 checkpoint inhibitors are under evaluation, particularly for subtypes like undifferentiated pleomorphic sarcoma and synovial sarcoma with higher mutational burdens. CAR-T cell therapy and cancer vaccines targeting cancer testis antigens are also being explored in preclinical and early-phase clinical trials.

Precision medicine is advancing further with biomarker-driven approaches. NTRK fusions, ALK rearrangements, and CDK4 amplifications are becoming targets for novel therapies, enabling drug repurposing across histologically distinct but genomically similar tumors. Companion diagnostics are being co-developed with these therapies to ensure accurate patient selection. Additionally, several academic-industry collaborations are pushing for pan-sarcoma registries and adaptive trial designs to overcome recruitment challenges and enable faster data accumulation across rare subtypes.

How Are Regional Healthcare Systems and Stakeholders Responding to Sarcoma Management Needs?

North America and Europe lead the global soft tissue sarcoma market in terms of diagnostics, research, and treatment access. The U.S. benefits from dedicated sarcoma centers and collaborative research networks such as the Sarcoma Alliance for Research through Collaboration (SARC), which accelerates clinical trial development and real-world evidence generation. Europe hosts several sarcoma reference networks under the European Reference Network on Rare Adult Solid Cancers (EURACAN), enhancing cross-border access to specialized care. Both regions are marked by favorable reimbursement policies for orphan drugs and strong institutional frameworks supporting rare cancer research.

In contrast, Asia Pacific exhibits significant disparity in STS management due to limited awareness, delayed diagnosis, and uneven access to advanced diagnostic tools and treatments. However, rising healthcare investments and the growth of private oncology centers in India, China, and Southeast Asia are gradually bridging these gaps. Japanese pharmaceutical firms and hospitals are notably involved in research on liposarcoma and gastrointestinal stromal tumors (GIST), while China is increasingly contributing to global clinical trial pipelines. Latin America and the Middle East & Africa regions face constraints in diagnosis and treatment access, but international non-profit collaborations and patient advocacy are improving care pathways in major urban centers.

Pharmaceutical companies are also reconfiguring their commercial strategies around sarcoma drugs by developing subtype-specific pipelines and forming partnerships with academic institutions to expand clinical trial access. The orphan drug designation and associated regulatory incentives-such as fast-track approvals, extended exclusivity, and R&D tax credits-are encouraging biotech startups to target ultra-rare sarcoma subtypes. Digital health platforms and AI-driven pathology tools are also being deployed to improve early detection and accelerate pathology workflows, especially in under-resourced settings.

What Is Driving the Expansion of the Soft Tissue Sarcoma Market and Where Are Opportunities Emerging?

The growth in the global soft tissue sarcoma market is driven by several factors including increasing awareness of rare cancers, expansion of personalized oncology, and the regulatory momentum supporting orphan drug development. The rising availability of histopathology and molecular testing services is leading to improved diagnostic accuracy, enabling early-stage detection and more effective treatment planning. Furthermore, increasing investments in cancer genomics and translational research are uncovering subtype-specific vulnerabilities, spurring targeted drug discovery efforts.

Governmental and institutional support for rare cancer management-through rare disease registries, funding grants, and interdisciplinary tumor boards-is improving patient identification and clinical trial recruitment. The introduction of real-world evidence platforms and global sarcoma patient databases is also supporting post-market surveillance and aiding clinical decision-making. In parallel, pharmaceutical companies are adopting adaptive trial designs to fast-track development of treatments for genetically defined STS subtypes. These innovations are helping overcome the limitations of small patient pools and heterogeneous clinical presentations.

Emerging opportunities lie in integrating digital pathology, AI-assisted image analysis, and liquid biopsy-based monitoring into sarcoma care pathways. These tools can enhance diagnostic precision and facilitate non-invasive monitoring of tumor recurrence. Additionally, the growing use of next-generation sequencing panels and companion diagnostics in routine oncology practice is expected to unlock greater value from targeted therapies. As pharmaceutical and diagnostic players converge around rare tumor targets, and health systems continue to enhance rare cancer infrastructure, the soft tissue sarcoma market is positioned for consistent growth, driven by scientific advances, policy support, and expanding patient engagement frameworks.

SCOPE OF STUDY:

The report analyzes the Soft Tissue Sarcoma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment, Other Treatment Types); End-Use (Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Aadi Bioscience, Inc.
  • Adaptimmune Therapeutics
  • Advenchen Laboratories
  • Agenus
  • AstraZeneca
  • Bayer AG
  • Chipscreen Biosciences, Ltd.
  • Chugai Pharma France
  • Eli Lilly and Company
  • Epizyme
  • GSK (GlaxoSmithKline)
  • Iovance Biotherapeutics
  • Jazz Pharmaceuticals
  • Mirati Therapeutics
  • Nanobiotix
  • Novartis
  • Plus Therapeutics, Inc.
  • Taiho Pharmaceuticals
  • Thermosome GmbH (THE001)
  • Tracon Pharmaceuticals Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38066

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Soft Tissue Sarcoma - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Rare Cancer Types Drives Investment in Soft Tissue Sarcoma Treatments
    • Growth in Personalized Oncology Enhances Molecular Targeting Approaches
    • Increased Use of Radiotherapy and Chemotherapy Combinations Boosts Treatment Uptake
    • Expansion of Immunotherapy Clinical Trials Spurs Therapeutic Advancements
    • FDA and EMA Orphan Drug Designations Accelerate Market Entry
    • Development of Biomarkers for Sarcoma Subtypes Supports Diagnostic Precision
    • Growing Adoption of Next-Generation Sequencing Enables Genetic Profiling
    • Collaborative Research Efforts Fuel Drug Discovery and Repurposing Initiatives
    • Patient Advocacy Group Involvement Improves Clinical Trial Enrollment
    • Integration of Digital Pathology Tools Enhances Diagnostic Accuracy
    • Rise in Multidisciplinary Cancer Care Centers Broadens Access to Sarcoma Therapies
    • Public-Private Partnerships Facilitate R&D in Rare Cancer Segments
    • Expansion of Soft Tissue Sarcoma Registries Strengthens Data-Driven Insights
    • Surge in Targeted Therapy Approval Rates Encourages Pharmaceutical Investment
    • Use of Robotic-Assisted Surgery Enhances Tumor Resection Outcomes
    • Increasing Insurance Coverage for Rare Cancers Expands Patient Accessibility
    • High Demand for Post-Treatment Monitoring Fuels Companion Diagnostic Development
    • Scientific Advances in Tumor Microenvironment Research Propel Innovation
    • Focus on Limb-Sparing Procedures Increases Need for Adjuvant Therapies
    • International Collaboration on Treatment Guidelines Promotes Standardized Care Pathways
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Soft Tissue Sarcoma Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Targeted Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Angiogenesis Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-Angiogenesis Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anti-Angiogenesis Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Specialty Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Soft Tissue Sarcoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Soft Tissue Sarcoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: India 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Soft Tissue Sarcoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Soft Tissue Sarcoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!